Arrowhead Pharmaceuticals (NASDAQ: ARWR)
Key Data Points
Arrowhead Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Arrowhead Pharmaceuticals Company Info
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
News & Analysis
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Is Arrowhead Pharmaceuticals a Buy Now?
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.
3 Biotech Stocks That Could Go Parabolic in 2022
Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Viking Therapeutics could be big winners this year.
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
Arrowhead Pharmaceuticals: Buy the Dip?
This biotech underdog has more than meets the eye.
Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today
A paused clinical trial with an important asset wasn't what investors wanted to hear today.
2 Monster Young Biotech Stocks to Add to Your Watchlist
These biotechs are fueling up for massive market launches.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.